137 related articles for article (PubMed ID: 8538482)
41. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
42. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
Adachi JD; Roux C; Pitt PI; Cooper C; Moniz C; Dequeker J; Ioannidis G; Cawley MI; Jenkins EA; Walker-Bone KE; Pack S; Stephenson GF; Laan RF; Brown J; Geusens P
J Rheumatol; 2000 Oct; 27(10):2424-31. PubMed ID: 11036840
[TBL] [Abstract][Full Text] [Related]
43. [Indications and limitations of non-hormonal treatments of osteoporosis].
Avouac B
Rev Fr Gynecol Obstet; 1993; 88(7-9):419-23. PubMed ID: 8235256
[TBL] [Abstract][Full Text] [Related]
44. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study.
Wimalawansa SJ
Am J Med; 1995 Jul; 99(1):36-42. PubMed ID: 7598140
[TBL] [Abstract][Full Text] [Related]
45. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
Herd RJ; Balena R; Blake GM; Ryan PJ; Fogelman I
Am J Med; 1997 Aug; 103(2):92-9. PubMed ID: 9274891
[TBL] [Abstract][Full Text] [Related]
46. Response to alendronate in osteoporosis after previous treatment with etidronate.
Fairney A; Kyd P; Thomas E; Wilson J
Osteoporos Int; 2000; 11(7):621-5. PubMed ID: 11069197
[TBL] [Abstract][Full Text] [Related]
47. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
Tuppurainen MT; Komulainen M; Kröger H; Honkanen R; Jurvelin J; Puntila E; Heikkinen AM; Alhava E; Saarikoski S
Osteoporos Int; 1998; 8(1):32-8. PubMed ID: 9692075
[TBL] [Abstract][Full Text] [Related]
48. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
Wang SX; Li H
Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
[TBL] [Abstract][Full Text] [Related]
49. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.
Hasling C; Charles P; Jensen FT; Mosekilde L
Osteoporos Int; 1994 Jul; 4(4):191-203. PubMed ID: 7949749
[TBL] [Abstract][Full Text] [Related]
50. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis.
Hwang JS; Tu ST; Yang TS; Chen JF; Wang CJ; Tsai KS
Osteoporos Int; 2006; 17(3):373-8. PubMed ID: 16421647
[TBL] [Abstract][Full Text] [Related]
51. Clinical experience with etidronate in osteoporosis.
Ryan PJ; Fogelman I
Clin Rheumatol; 1994 Sep; 13(3):455-8. PubMed ID: 7835009
[TBL] [Abstract][Full Text] [Related]
52. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
[TBL] [Abstract][Full Text] [Related]
53. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up).
Meunier PJ; Confavreux E; Tupinon I; Hardouin C; Delmas PD; Balena R
J Clin Endocrinol Metab; 1997 Sep; 82(9):2784-91. PubMed ID: 9284696
[TBL] [Abstract][Full Text] [Related]
54. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
55. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
[TBL] [Abstract][Full Text] [Related]
56. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate.
Iwamoto J; Takeda T; Ichimura S
J Orthop Sci; 2001; 6(6):487-92. PubMed ID: 11793169
[TBL] [Abstract][Full Text] [Related]
57. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
Nakamura T; Maekawa S; Morinobu S; Morinobu A; Koshiba M; Yamauchi M; Sugimoto T; Kumagai S
Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
[TBL] [Abstract][Full Text] [Related]
58. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
Adachi JD; Bensen WG; Brown J; Hanley D; Hodsman A; Josse R; Kendler DL; Lentle B; Olszynski W; Ste-Marie LG; Tenenhouse A; Chines AA
N Engl J Med; 1997 Aug; 337(6):382-7. PubMed ID: 9241127
[TBL] [Abstract][Full Text] [Related]
59. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.
Mandema JW; Zheng J; Libanati C; Perez Ruixo JJ
J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115
[TBL] [Abstract][Full Text] [Related]
60. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
Overgaard K
Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]